NASDAQ:MYNZ Mainz Biomed (MYNZ) Stock Price, News & Analysis $1.12 +0.09 (+8.74%) As of 10/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsNews and TrendsOwnershipSEC Filings About Mainz Biomed Stock (NASDAQ:MYNZ) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$1.02▼$1.1350-Day Range$1.03▼$1.6052-Week Range$0.55▼$4.43Volume545,557 shsAverage Volume371,589 shsMarket Capitalization$10.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Mainz Biomed N.V. (NASDAQ: MYNZ) is a molecular genetics diagnostic company focused on the early detection of cancer and other medical conditions. The company develops noninvasive diagnostic tests designed to identify disease-related genetic markers from patient samples. Its lead product, ColoAlert, is an at-home, stool-based screening test for colorectal cancer. The test analyzes stool samples for specific DNA biomarkers associated with colorectal cancer and precancerous lesions, along with occult blood. ColoAlert is intended to provide a convenient, noninvasive screening option that can complement established colorectal cancer screening methods. Founded in 2016 and headquartered in Mainz, Germany, Mainz Biomed has commercial and clinical development activities in Europe and has pursued expansion into the United States. The company’s U.S. development program has included clinical studies intended to support regulatory clearance and broader adoption of ColoAlert.AI Generated. May Contain Errors. Read More Receive MYNZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MYNZ Stock News HeadlinesReviewing TAT Technologies (NASDAQ:TATT) and Mainz Biomed (NASDAQ:MYNZ)October 4, 2026 | americanbankingnews.comMainz BioMed NV: Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors / Name change to Quantum Cyber (QUCY)March 12, 2026 | finanznachrichten.deALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 15 at 1:00 AM | Weiss Ratings (Ad)Strategische Neuausrichtung: Mainz Biomed firmiert in Quantum Cyber um und ernennt neuen ChairmanMarch 11, 2026 | de.investing.comMainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of DirectorsMarch 11, 2026 | globenewswire.comMainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood SamplesFebruary 24, 2026 | markets.businessinsider.comMainz Biomed sichert sich 6 Millionen US-Dollar und richtet Fokus auf BauchspeicheldrüsenkrebsFebruary 17, 2026 | de.investing.comMainz Biomed secures $6 million private placement, shifts focus to US pancreatic cancer programFebruary 17, 2026 | msn.comSee More Headlines MYNZ Stock Analysis - Frequently Asked Questions How have MYNZ shares performed this year? Mainz Biomed's stock was trading at $1.12 at the beginning of the year. Since then, MYNZ stock has increased by 0.0% and is now trading at $1.12. How were Mainz Biomed's earnings last quarter? Mainz Biomed NV (NASDAQ:MYNZ) posted its earnings results on Tuesday, August, 15th. The company reported ($22.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($16.80) by $5.60. The firm had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.25 million. When did Mainz Biomed's stock split? Mainz Biomed shares reverse split on the morning of Tuesday, December 3rd 2024.The 1-40 reverse split was announced on Friday, November 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Mainz Biomed IPO? Mainz Biomed (MYNZ) raised $10 million in an IPO on Friday, November 5th 2021. The company issued 2,000,000 shares at $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mainz Biomed? Shares of MYNZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mainz Biomed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mainz Biomed investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Intel (INTC), Palantir Technologies (PLTR), SoFi Technologies (SOFI), Tesla (TSLA) and Plug Power (PLUG). Company Calendar Last Earnings8/15/2023Today10/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Aerospace & Defense Sub-IndustryAerospace & Defense Current SymbolNASDAQ:MYNZ CIK1874252 Webmainzbiomed.com Phone49-6131-554-2860FaxN/AEmployees30Year Founded2021Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.44 Current Ratio0.52 Quick Ratio0.43 Sales & Book Value Annual Sales$659.94 thousand Price / Sales15.38 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book0.43Miscellaneous Outstanding Shares9,060,000Free Float7,411,000Market Cap$10.15 million OptionableNot Optionable Beta0.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:MYNZ) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
